JP2022537289A5 - - Google Patents

Info

Publication number
JP2022537289A5
JP2022537289A5 JP2021574798A JP2021574798A JP2022537289A5 JP 2022537289 A5 JP2022537289 A5 JP 2022537289A5 JP 2021574798 A JP2021574798 A JP 2021574798A JP 2021574798 A JP2021574798 A JP 2021574798A JP 2022537289 A5 JP2022537289 A5 JP 2022537289A5
Authority
JP
Japan
Application number
JP2021574798A
Other languages
Japanese (ja)
Other versions
JPWO2020257289A5 (https=
JP2022537289A (ja
JP7716342B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038143 external-priority patent/WO2020257289A2/en
Publication of JP2022537289A publication Critical patent/JP2022537289A/ja
Publication of JP2022537289A5 publication Critical patent/JP2022537289A5/ja
Publication of JPWO2020257289A5 publication Critical patent/JPWO2020257289A5/ja
Application granted granted Critical
Publication of JP7716342B2 publication Critical patent/JP7716342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021574798A 2019-06-17 2020-06-17 Cd138に対するヒト化抗体分子およびその使用 Active JP7716342B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962862457P 2019-06-17 2019-06-17
US62/862,457 2019-06-17
US202063035323P 2020-06-05 2020-06-05
US63/035,323 2020-06-05
PCT/US2020/038143 WO2020257289A2 (en) 2019-06-17 2020-06-17 Humanized antibody molecules to cd138 and uses thereof

Publications (4)

Publication Number Publication Date
JP2022537289A JP2022537289A (ja) 2022-08-25
JP2022537289A5 true JP2022537289A5 (https=) 2023-06-26
JPWO2020257289A5 JPWO2020257289A5 (https=) 2023-06-26
JP7716342B2 JP7716342B2 (ja) 2025-07-31

Family

ID=71995040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574798A Active JP7716342B2 (ja) 2019-06-17 2020-06-17 Cd138に対するヒト化抗体分子およびその使用

Country Status (14)

Country Link
US (2) US12338291B2 (https=)
EP (1) EP3983442A2 (https=)
JP (1) JP7716342B2 (https=)
KR (1) KR20220044939A (https=)
CN (1) CN114269786B (https=)
AU (1) AU2020294696A1 (https=)
BR (1) BR112021025421A2 (https=)
CA (1) CA3142021A1 (https=)
IL (1) IL289034A (https=)
MX (1) MX2021016098A (https=)
MY (1) MY210065A (https=)
PH (1) PH12021553109A1 (https=)
TW (1) TW202112822A (https=)
WO (1) WO2020257289A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003783A (es) 2017-10-02 2021-01-08 Visterra Inc Moleculas de anticuerpo de cd138 y sus usos.
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
US20240319194A1 (en) * 2021-06-29 2024-09-26 Sheba Impact Ltd. Diagnosis and treatment of pancreatic cancer
WO2023097254A1 (en) * 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
US20250064933A1 (en) * 2021-12-30 2025-02-27 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors comprising a pdz binding motif
CN115960231A (zh) * 2022-09-28 2023-04-14 合肥天港免疫药物有限公司 抗cd138的抗体及其应用
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP1356093A2 (en) * 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US20070054332A1 (en) 2005-08-10 2007-03-08 Alan Rapraeger Syndecan 1 ectodomain inhibits cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2240516B1 (en) 2007-12-26 2015-07-08 Biotest AG Methods and agents for improving targeting of cd138 expressing tumor cells
JP2011507933A (ja) 2007-12-26 2011-03-10 バイオテスト・アクチエンゲゼルシヤフト 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
CA2710453C (en) 2007-12-26 2019-07-02 Biotest Ag Agents targeting cd138 and uses thereof
ES2526433T3 (es) 2007-12-26 2015-01-12 Biotest Ag Inmunoconjugados dirigidos a CD138 y usos de los mismos
NZ613647A (en) 2009-05-06 2015-02-27 Biotest Ag Uses of immunoconjugates targeting cd138
US9249467B2 (en) 2011-09-16 2016-02-02 Steven Goodison Bladder cancer detection composition, kit and associated methods
US10577543B2 (en) 2011-10-27 2020-03-03 Raymond Roger Wallage Efficient oil shale recovery method
MX358680B (es) 2011-12-08 2018-08-31 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
KR101721678B1 (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN103103197A (zh) 2013-01-30 2013-05-15 百奇生物科技(苏州)有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
RU2611685C2 (ru) * 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
CN110691793A (zh) 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1(cd138)结合剂及其用
MX2020003783A (es) * 2017-10-02 2021-01-08 Visterra Inc Moleculas de anticuerpo de cd138 y sus usos.
JOP20200268A1 (ar) 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
CN114144437B (zh) 2019-06-07 2025-02-25 阿迪马布有限责任公司 工程化的pH依赖性抗CD3抗体及其产生和使用方法
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
US12590171B2 (en) * 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof

Similar Documents

Publication Publication Date Title
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
CH718816A4 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)
BR102021015220A2 (https=)
BR102021015247A2 (https=)
BR102021014056A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012003A2 (https=)
BR102021012107A2 (https=)
BR102021010467A2 (https=)
BR102021009555A2 (https=)